Selinexor plus talazoparib for advanced triple-negative breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests selinexor plus talazoparib in people with advanced, treatment-resistant solid tumors and, separately, advanced triple-negative breast cancer. It aims to see whether this combination can shrink tumors or slow their growth when standard options have not worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and able to sign consent
- You must not have taken talazoparib or any other PARP inhibitor before
- You must not have taken selinexor before
- Your cancer must be measurable on scans, and you should be well enough to do daily activities (ECOG 0–1)
- Your blood counts and organ function (bone marrow, liver, kidneys) must be strong enough for treatment
- You must not be pregnant or breastfeeding, and you must use effective birth control if able to become pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, selinexor and gemcitabine, for people with a type of soft-tissue sarcoma (leiomyosarcoma or malignant peripheral nerve sheath tumor) that has spread or cannot be surgically removed and has gotten worse despite at least one prior treatment. The goal is to see if this combination can help shrink or slow the cancer.
This trial tests a chemotherapy drug (temozolomide) alone or combined with a targeted therapy (olaparib) for people with triple negative breast cancer. It may help if your tumor has a specific genetic marker (MGMT promoter methylation).
This trial tests a three-drug combination (selinisole, azacitidine, and venetoclax) for newly diagnosed high-risk blood cancers with a TP53 gene change. These drugs aim to target the cancer while skipping standard chemotherapy, possibly making treatment more effective and less harsh.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
This study tests a drug called olaparib (a PARP inhibitor) in people with triple-negative breast cancer that has returned or spread, and whose tumors do not have a BRCA gene mutation but do have a change called BRCA1 promoter methylation. The goal is to see if olaparib can help shrink or slow the cancer, based on this specific tumor feature.
Hear when a new Advanced Refractory Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.